Join the 'Aspergillosis - Invasive' group to help and get support from people like you.
Aspergillosis - Invasive News
Related terms: Aspergillosis, invasive pulmonary
FDA Medwatch Alert: Noxafil (posaconazole): Drug Safety Communication - Dosing Errors when Switching between Different Oral Formulations; Label Changes Approved
Posted 4 Jan 2016 by Drugs.com
ISSUE: The FDA is cautioning that differences in dosing regimens between the two oral formulations of the antifungal Noxafil (posaconazole) have resulted in dosing errors. To help prevent additional medication errors, the drug labels were revised to indicate that the two oral formulations cannot be directly substituted for each other but require a change in dose. Direct mg for mg substitution o ...
Posted 8 Mar 2015 by Drugs.com
FRIDAY, March 6, 2015 – Cresemba (isavuconazonium sulfate) has been approved by the U.S. Food and Drug Administration to treat rare but serious fungal infections, mostly affecting people with weakened immune systems, the agency said Friday in a news release. The infections are caused by Aspergillus and Mucorales fungi. The new drug, targeting the cell walls of the fungi, is available in oral and ...
Posted 6 Mar 2015 by Drugs.com
March 6, 2015 – The U.S. Food and Drug Administration today approved Cresemba (isavuconazonium sulfate), a new antifungal drug product used to treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections. Aspergillosis is a fungal infection caused by Aspergillus species, and mucormycosis is caused by the Mucorales fungi. These infections occur most often in ...
Related Condition Support Groups
Related Drug Support Groups
itraconazole, voriconazole, Sporanox, amphotericin b, AmBisome, amphotericin b liposomal, Fungizone, Cancidas, amphotericin b lipid complex, view more... Vfend, Cresemba, caspofungin, posaconazole, isavuconazonium, Amphotec, amphotericin b cholesteryl sulfate, Amphocin, Abelcet, Sporanox PulsePak, Noxafil, Onmel